← Back to headlines
AstraZeneca's $1.5 billion lung cancer investment
AstraZeneca has made a significant $1.5 billion investment in lung cancer research and development, with questions arising about whether its new drug Zegfrovy can bolster its oncology growth.
23 Aug, 19:38 — 23 Aug, 19:38
Sources
Showing 1 of 1 sources
